Zydus Lifesciences has revised the terms of its proposed share buyback by increasing the repurchase price while reducing the number of shares to be bought back under the offer. The company on Wednesday said its Buyback Committee, at a meeting held today, approved an increase in the buyback price to Rs 1,260 per equity share from the earlier announced Rs 1,150 per share.
Simultaneously, the drugmaker reduced the maximum number of shares proposed to be repurchased to 87.3 lakh equity shares from 95.65 lakh shares announced earlier. The revised buyback size represents up to 0.87% of the company’s paid-up equity share capital.
However, the total buyback outlay remains unchanged at up to Rs 1,100 crore.
The buyback will be undertaken through the tender offer route on a proportionate basis in accordance with the Sebi’s buyback regulations.
Zydus Lifesciences had earlier announced the buyback proposal through a public announcement dated May 20, 2026.
The shares of Zydus Life have rallied 19% over a one-year period, outperforming benchmarks Nifty and the BSE Sensex, whose returns in the same period are at a negative 4% and 8%, respectively.
Today was the last day to buy company's shares to participate in the share buyback. The pharma company fixed the record date to determine shareholder eligibility for the corporate action on May 29 (Friday). Only those shareholders who own the shares of the company in their demat accounts as on the record date will be eligible to tender shares.
As per Sebi's T+1 settlement norm, investors must buy the company's shares at least one trading day before the record date so that they are credited to their demat accounts by that date, making them eligible for the reward.
Zydus Lifesciences reported a consolidated net profit of Rs 1,272.5 crore for the January-March quarter of FY26, marking a 9% increase from the Rs 1,171 crore profit reported in the corresponding quarter of the previous financial year.
The company’s revenue from operations rose more than 16% year-on-year to Rs 7,587 crore during the quarter under review, compared with Rs 6,528 crore in the year-ago period.
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)
